News

A combination of Opsumit (macitentan) plus Adcirca (tadalafil) lowered pulmonary vascular resistance — a measure showing how well blood flows through vessels — by 47% in people newly diagnosed with pulmonary arterial hypertension (PAH) and improved their physical capacity, new data show. Olivier Sitbon, MD, PhD, with Université Paris–Sud presented the…

Higher levels of a protein involved in certain immune responses, called soluble suppression of tumorigenicity-2 (sST2), are associated with more severe pulmonary hypertension (PH) and heart dysfunction, a study found. This protein’s potential use as a prognostic biomarker for PH, however, seems to be limited. The study, “The Prognostic Value of…

Adcirca (tadalafil) helped to improve survival in dogs with pulmonary hypertension (PH), a new study suggests. Knowing the underlying conditions associated with PH can lead to improved health outcomes in dogs, the study stated. The findings might also prove to be important in understanding the disease in humans.

Treatment with Adcirca (tadalafil) plus Opsumit (macitentan) can provide functional benefits and lessen symptoms in newly diagnosed patients with pulmonary arterial hypertension (PAH), results from a clinical trial show. The data will be discussed at the upcoming CHEST Annual Meeting 2019, to be held Oct. 19-23…

To help those with heart and circulatory disorders live longer and better lives, the British Heart Foundation (BHF) has awarded the University College London (UCL) a £1 million grant (about $1.28 million) over five years. Specifically, funding from the BHF Research Accelerator Award will help UCL build a…

The mechanics of pulmonary hypertension (PH) create a cascade of events that affect the cardiovascular system, kidneys, respiratory system, and digestive system.  Though symptoms, which persist over time, primarily lead to changes in breathing…

Respira Therapeutics has regained full worldwide research, development, and licensing rights over its inhaled medicine-device combination product, called RT234, for the treatment of pulmonary arterial hypertension (PAH). This follows the decision of its partner United Therapeutics to terminate the collaboration with Respira, which was established…

Pulmonary hypertension contributes to markedly poorer outcomes and doubles a risk of death in people with moderate-to-severe problems in the heart’s tricuspid valve, a condition known as tricuspid regurgitation, a study from Europe reports. The study, “Impact of pulmonary hypertension on outcome in patients with moderate or severe…

Measuring the levels of an inflammatory protein known as HMGB1 may help diagnose persistent pulmonary hypertension of the newborn (PPHN) and monitor its progression, according to a study in patients and in a rat model. The research, “High mobility group box 1 protein (HMGB1) as biomarker…

Loss of a hormone called secretin (SCT) induces hypertension, scarring, and structural alterations in the heart and lungs, a study in mice reports. The study “Loss of secretin results in systemic and pulmonary hypertension with cardiopulmonary pathologies in mice” was published in the journal Nature Scientific Reports, and…

Oral treatment with rodatristat ethyl is safe and well-tolerated, according to results from two completed Phase 1 clinical studies in healthy volunteers. These positive results support advancing the investigational therapy into Phase 2 studies involving people with pulmonary arterial hypertension (PAH), the treatment’s developer says. The most recent…

Halting a protein called Slug may help reduce the severity of increased blood pressure related to lung scarring — a condition called pulmonary hypertension (PH) secondary to pulmonary fibrosis, or PF-PH, a new animal study shows. The study, “Histological hallmarks and role of Slug/PIP axis…